Navigation Links
Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
Date:5/7/2008

to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines and the risk that the current Phase 2b study of TRU-015 does not help the Company and Wyeth identify a TRU-015 induction dosing regimen or further establish the most effective treatment regimen for TRU-015, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, the risk that the Company does not achieve the financial and operating results it expects and such other risks as identified in the company's quarterly report on Form 10-K for the period ended Dec. 31, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, contact:

Trubion Pharmaceuticals Inc.

Jim DeNike

Senior Director, Corporate Communication

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

<
'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , a ... announced today that T. (Teo) Forcht Dagi , ... company,s Board of Directors. " Teo Forcht ... in neurosurgery, medical innovation and venture capital," said Remis ... delighted to add his clinical, strategic, and entrepreneurial expertise to ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... DUBLIN , August 29, 2014 ... management and collaboration software has announced a major new ... services, founded by renowned pathology expert, Dr. Marius ... advance of the 26th European Congress of Pathology which ... in the ExCeL Arena, London ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... April 14, 2011 Reportlinker.com announces that a new ... Neuropathy Therapy Area Pipeline Report ... Area Pipeline Report contains detailed information on the neuropathy ... status of neuropathy drugs by company and by stage ...
... 14, 2011 Reportlinker.com announces that a new ... Juvenile Rheumatoid Arthritis (JRA) Therapeutics ... http://www.reportlinker.com/p0479828/Juvenile-Rheumatoid-Arthritis-JRA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html ... and Market Forecasts to 2017 ...
Cached Medicine Technology:Reportlinker Adds Neuropathy Therapy Area Pipeline Report 2Reportlinker Adds Neuropathy Therapy Area Pipeline Report 3Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8
(Date:8/29/2014)... August 29, 2014 Healthpointe is proud ... Rodas. Dr. Rodas will be practicing out of Healthpointe’s ... a member of Healthpointe’s orthopedic team, Dr. ... medicine, and board-certified in occupational medicine. , Among ... as Medical Director of Raytheon, the world-class defense and ...
(Date:8/29/2014)... La Miraca, California (PRWEB) August 29, 2014 ... clinical training to Chapman University Physical Therapy students ... students at Chapman University will be shadowing Healthpointe ... which will allow them to develop clinical experience ... University Physical Therapy students will gain insight into ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pursuing its ... is set to unveil a stunning new design that ... company figures, the highly notable surrogacy platform has witnessed ... With over 13,000 visitors a month, the FindSurrogateMother.com community ... working toward one common goal — the precious gift ...
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Elk Grove Village, IL (PRWEB) August 29, 2014 ... an innovator in hearing wellness solutions, is on its ... Sept. 15-17 at the San Diego Convention Center to ... for those who work in high-noise industrial environments. Etymotic’s ... among the hottest wearable technology devices at the show. ...
Breaking Medicine News(10 mins):Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
... Reporter , TUESDAY, May 15 (HealthDay News) -- With the ... new study on air quality during the 2008 Beijing Olympics ... could lower the risk of heart trouble for many. ... advantage of changes in air quality surrounding the 2008 Olympics, ...
... , TUESDAY, May 15 (HealthDay News) -- The ... were saved between 2004 and 2008 by the U.S. President,s ... The program reduced adults, risk of death from all causes ... Stanford University School of Medicine researchers found. The researchers said ...
... An increasingly common and safer type of surgery for kidney ... sicker and poorer patients who are uninsured or rely on ... new study by researchers at Henry Ford Hospital. The ... portion of a cancerous kidney, leaving the unaffected part to ...
... better mousetrap, a team of Rice University freshmen took a ... children in the developing world. "The goal was to ... could prevent over-hydration and under-hydration," said Melissa Yuan, a member ... a mechanical engineering major. "It,s designed to be used in ...
... Although people with a family history of high blood pressure ... themselves, regular exercise and physical fitness may significantly lower that ... of this study send a very practical message, which is ... which we define as brisk walking for 150 minutes per ...
... Hospital (MGH) researchers suggests that specific populations of tumor cells ... new copies of themselves and grow. In their report ... researchers identify a tumor-propagating cell required for the growth of ... show that another, more-differentiated tumor cell must first travel to ...
Cached Medicine News:Health News:Beijing's Olympic Smog Shows Pollution's Effect on Health 2Health News:Beijing's Olympic Smog Shows Pollution's Effect on Health 3Health News:Safer kidney cancer surgery under-used for poorer, sicker Medicare, Medicaid patients 2Health News:This 'mousetrap' may save lives 2Health News:Fitness Fights High Blood Pressure, Even With Family History 2Health News:All cancer cells are not created equal 2Health News:All cancer cells are not created equal 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
Medicine Products: